Medical research

New England Journal of Medicine Publishes Results of the PULSAR Phase 2 Trial of Sotatercept in Patients with Pulmonary Arterial Hypertension

Retrieved on: 
Thursday, April 1, 2021
Research, Infectious diseases, Clinical trials, Cardiology, Biotechnology, Health, Pharmaceutical, Other Science, Science, Hypertension, Pulmonary hypertension, Placebo-controlled study, Chemical compounds, PAH, Medical research, Chloroarenes, Organic compounds, Riociguat, the PULSAR Trial, Sotatercept, PAH, Acceleron

This is a result that suggests that sotatercept could bring an important new mechanistic approach to the treatment of patients with PAH.

Key Points: 
  • This is a result that suggests that sotatercept could bring an important new mechanistic approach to the treatment of patients with PAH.
  • The PULSAR publication marks the third time that trial results of an Acceleron-discovered therapy have been published in the New England Journal of Medicine in the past 15 months.
  • The PULSAR Phase 2 trial is a randomized, double-blind, placebo-controlled study designed to evaluate the efficacy and safety of sotatercept in patients with PAH.
  • In pulmonary, Acceleron is developing sotatercept for the treatment of pulmonary arterial hypertension (PAH), having reported positive topline results of the PULSAR Phase 2 trial.

Revance to Showcase Phase 3 Results Evaluating DaxibotulinumtoxinA for Injection for the Treatment of Cervical Dystonia at the American Academy of Neurology Annual 2021 Virtual Meeting

Retrieved on: 
Thursday, April 1, 2021
Biotechnology, Pharmaceutical, Health, Clinical trials, Health sciences, Clinical research, Design of experiments, Health, Medical research, Clinical pharmacology, Clinical trial, Pharmaceutical industry, Lanadelumab, Palifermin, Cervical Dystonia, Revance Therapeutics, Inc.

Revance will present results from its ASPEN-1 Phase 3 clinical trial evaluating the efficacy and safety of DaxibotulinumtoxinA for Injection for the treatment of cervical dystonia in adults.

Key Points: 
  • Revance will present results from its ASPEN-1 Phase 3 clinical trial evaluating the efficacy and safety of DaxibotulinumtoxinA for Injection for the treatment of cervical dystonia in adults.
  • Randomized Trial (ASPEN-1): Patients were randomized to a single treatment of either 125 Unit or 250 Unit dose of DaxibotulinumtoxinA for Injection, or placebo.
  • Open-Label Study (ASPEN-OLS): Patients receive up to four sequential treatment cycles of DaxibotulinumtoxinA for Injection over the 52-week observation period.
  • Primary endpoints of the trial are safety and immunogenicity after multiple cycles of treatment with DaxibotulinumtoxinA for Injection.

Pfizer and BioNTech Confirm High Efficacy and No Serious Safety Concerns Through Up to Six Months Following Second Dose in Updated Topline Analysis of Landmark COVID-19 Vaccine Study

Retrieved on: 
Thursday, April 1, 2021
COVID-19, Health sciences, Medicine, COVID-19 vaccines, Clinical trials, Medical research, BioNTech, BioNTech, Societates Europaeae, Pfizer, Vaccine, COVID-19 vaccine

The high vaccine efficacy observed through up to six months following a second dose and against the variant prevalent in South Africa provides further confidence in our vaccines overall effectiveness.

Key Points: 
  • The high vaccine efficacy observed through up to six months following a second dose and against the variant prevalent in South Africa provides further confidence in our vaccines overall effectiveness.
  • Results from this analysis of 46,307 trial participants build upon and confirm previously released data and demonstrate strong protection against COVID-19 through six months post-second dose.
  • Efficacy was generally consistent across age, gender, race and ethnicity demographics, and across participants with a variety of underlying conditions.
  • The vaccine, which is based on BioNTech proprietary mRNA technology, was developed by both BioNTech and Pfizer.

Pfizer and BioNTech Confirm High Efficacy and No Serious Safety Concerns Through Up to Six Months Following Second Dose in Updated Topline Analysis of Landmark COVID-19 Vaccine Study

Retrieved on: 
Thursday, April 1, 2021
Infectious diseases, FDA, Clinical trials, Biotechnology, Other Health, Health, Pharmaceutical, General Health, Oncology, COVID-19, Health sciences, Medicine, COVID-19 vaccines, Clinical trials, Medical research, BioNTech, BioNTech, Societates Europaeae, Pfizer, Vaccine, COVID-19 vaccine

The high vaccine efficacy observed through up to six months following a second dose and against the variant prevalent in South Africa provides further confidence in our vaccines overall effectiveness.

Key Points: 
  • The high vaccine efficacy observed through up to six months following a second dose and against the variant prevalent in South Africa provides further confidence in our vaccines overall effectiveness.
  • Results from this analysis of 46,307 trial participants build upon and confirm previously released data and demonstrate strong protection against COVID-19 through six months post-second dose.
  • Efficacy was generally consistent across age, gender, race and ethnicity demographics, and across participants with a variety of underlying conditions.
  • The vaccine, which is based on BioNTech proprietary mRNA technology, was developed by both BioNTech and Pfizer.

Government of Canada COVID-19 Update for Indigenous Peoples and Communities

Retrieved on: 
Thursday, April 1, 2021
COVID-19 vaccines, Medical research

As of March 30 the Government of Nunavut is also reporting no active cases of COVID-19.

Key Points: 
  • As of March 30 the Government of Nunavut is also reporting no active cases of COVID-19.
  • Since the beginning of the COVID-19 pandemic, The Canadian Armed Forces (CAF) has been providing vital assistance to Indigenous communities across Canada, to minimize the impacts of the COVID-19 pandemic.
  • In Alberta, the Mtis Nation of Alberta launched the first Mtis-led vaccine clinic in Canada in Edmonton this week, in collaboration with the provincial government.
  • In Quebec, all First Nations communities have started vaccination clinics, and four communities have started their second doses, with the rest to begin in the coming weeks.

Rubix LS Launches Therapeutics Division

Retrieved on: 
Wednesday, March 31, 2021
Biotechnology, Pharmaceutical, Health, Clinical trials, Health sciences, Health, Clinical pharmacology, Clinical research, Clinical trial, Design of experiments, Pharmaceutical industry, Medical research

[RUBIX LS], a minority-led life science research firm focusing on solutions to support minorities within clinical trials, announced today that it has formally launched its therapeutics division.

Key Points: 
  • [RUBIX LS], a minority-led life science research firm focusing on solutions to support minorities within clinical trials, announced today that it has formally launched its therapeutics division.
  • While the industry remains challenged on supporting clinical research inclusion reeling from the devastating effects of the COVID-19 pandemic, Rubix is positioning its lead clinical trial platform to catalyze innovations for designing and developing therapeutics that will target conditions exhibited by minority and under-represented patient populations.
  • These investments will allow Rubix LS to expand its growing product pipeline for decisive and inclusive health outcomes in various disease states in the coming months.
  • For more information about Rubix LS visit its website at www.rubixls.com
    View source version on businesswire.com: https://www.businesswire.com/news/home/20210331005625/en/

COVID-19 Vaccination Appointments Open at Georgia, South Carolina and Virginia Publix Pharmacies

Retrieved on: 
Wednesday, March 31, 2021
Retail, Health, Infectious diseases, Supermarket, General Health, Pharmaceutical, Publix, Medical research, COVID-19 vaccine, Economy of the United States, Companies, Health care

Starting Thursday, April 1, at 7 a.m. Eastern time, the online appointment reservation system will open for Moderna COVID-19 vaccination appointments at 142 Georgia, 62 South Carolina and 16 Virginia Publix Pharmacy locations.

Key Points: 
  • Starting Thursday, April 1, at 7 a.m. Eastern time, the online appointment reservation system will open for Moderna COVID-19 vaccination appointments at 142 Georgia, 62 South Carolina and 16 Virginia Publix Pharmacy locations.
  • View a full list of South Carolina pharmacies offering appointments for the COVID-19 vaccine.
  • Publix pharmacies will administer the vaccine in the following Virginia counties, while supplies last: Chesterfield, Colonial Heights, Henrico, Spotsylvania and Stafford.
  • Publix, the largest employee-owned company in the U.S. with more than 225,000 associates, currently operates 1,269 stores in Florida, Georgia, Alabama, Tennessee, South Carolina, North Carolina and Virginia.

Iconovo signs agreement with ISR for the development of inhaled covid-19 vaccine

Retrieved on: 
Wednesday, March 31, 2021
Medical research, Medicine, Health sciences, Expense, Intellectual property law, Patent law, Royalty payment, COVID-19 vaccine, Vaccine, Medical specialties

The agreement includes stepwise payments of a 9 MSEK technology access fee, set up as five increasing milestone payments over the development to market authorization.

Key Points: 
  • The agreement includes stepwise payments of a 9 MSEK technology access fee, set up as five increasing milestone payments over the development to market authorization.
  • Additionally, the agreement will give Iconovo low single-digit percentage royalties over a period of 14 years from market launch.
  • The size of the sales potential for an inhaled covid vaccine will depend on the rate of vaccination in these countries.
  • Iconovo is a global leader and wants to act as a driving force in this development," said Johan Wborg.

Iconovo signs agreement with ISR for the development of inhaled covid-19 vaccine

Retrieved on: 
Wednesday, March 31, 2021
Medical research, Medicine, Health sciences, Expense, Intellectual property law, Patent law, Royalty payment, COVID-19 vaccine, Vaccine, Medical specialties

The agreement includes stepwise payments of a 9 MSEK technology access fee, set up as five increasing milestone payments over the development to market authorization.

Key Points: 
  • The agreement includes stepwise payments of a 9 MSEK technology access fee, set up as five increasing milestone payments over the development to market authorization.
  • Additionally, the agreement will give Iconovo low single-digit percentage royalties over a period of 14 years from market launch.
  • The size of the sales potential for an inhaled covid vaccine will depend on the rate of vaccination in these countries.
  • Iconovo is a global leader and wants to act as a driving force in this development," said Johan Wborg.

MEDIA ADVISORY: Facebook Live with Dr. Theresa Tam - Your COVID-19 Vaccine Questions Answered

Retrieved on: 
Wednesday, March 31, 2021
Software, Medical research, Operating systems, World Wide Web, COVID-19 vaccine, Facebook, COVID-19 vaccination in Canada, Vaccine Choice Canada

TORONTO, March 31, 2021 /CNW/ - Working with the Government of Canada, today at 1-1:30PM ET, Facebook Canada is hosting Your COVID-19 Vaccine Questions Answered, a Facebook Live event with Canada's top doctors to connect millions of Canadians with trusted COVID-19 vaccine information.

Key Points: 
  • TORONTO, March 31, 2021 /CNW/ - Working with the Government of Canada, today at 1-1:30PM ET, Facebook Canada is hosting Your COVID-19 Vaccine Questions Answered, a Facebook Live event with Canada's top doctors to connect millions of Canadians with trusted COVID-19 vaccine information.
  • Now, as COVID-19 vaccines begin to roll out, Facebook is using its scale to connect billions of people with accurate health information about these vaccines.
  • WHAT: Facebook Live with Canada's top doctors, including Dr. Theresa Tam, Canada's Chief Public Health Officer, to answer Canadians' COVID-19 vaccine questions.
  • WHERE: Live on Facebook Canada's Page: https://www.facebook.com/facebookappCanada
    Canadians can now let friends and family know about their plans to get the #CovidVaccine by adding a frame on their Facebook profile picture: When it's my turn, I'll get the COVID-19 vaccine OR I got the COVID-19 vaccine .